Advertisement
Screener

ORGANOGENESIS HOLDINGS INC. (ORGO) Overview

ORGANOGENESIS HOLDINGS INC. (ORGO) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.77; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.44; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 0.11; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.10; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$1.29$1.80$2.52$3.52$4.92$6.872025-09-292026-09-29$1.29$2.12$3.49$5.73$9.42$15.482021-09-292026-09-29$1.29$3.38$8.82$23.06$60.27$157.502017-01-052026-09-29$1.29$3.38$8.82$23.06$60.27$157.502017-01-052026-09-29$1.29$3.38$8.82$23.06$60.27$157.502017-01-052026-09-29

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$1.39
Previous close
$1.38
Change
$0.01
Change (%)
0.36%
Close date
2026-09-29
Previous close date
2026-09-28
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

ORGO
-73.26%
S&P 500
(m)

1 year

ORGO
-67.49%
S&P 500
(m)

3 years

ORGO
-56.45%
S&P 500
(m)

5 years

ORGO
-90.60%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.77

-0.85-0.56-0.280.010.2931 Mar 2025: estimate (m); actual -0.1731 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.1030 Jun 2025(m)30 Sept 2025: estimate (m); actual 0.1130 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.4431 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.7730 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.77(m)(m)
1 Jan 202631 Mar 2026(m)-0.44(m)(m)
1 Jul 202530 Sept 2025(m)0.11(m)(m)
1 Apr 202530 Jun 2025(m)-0.10(m)(m)
1 Jan 202531 Mar 2025(m)-0.17(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual 0.15

-0.090.150.390.640.8831 Dec 2021: estimate (m); actual 0.7031 Dec 2021(m)31 Dec 2022: estimate (m); actual 0.1231 Dec 2022(m)31 Dec 2023: estimate (m); actual 0.0431 Dec 2023(m)31 Dec 2024: estimate (m); actual -0.0131 Dec 2024(m)31 Dec 2025: estimate (m); actual 0.1531 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)0.15(m)(m)
1 Jan 202431 Dec 2024(m)-0.01(m)(m)
1 Jan 202331 Dec 2023(m)0.04(m)(m)
1 Jan 202231 Dec 2022(m)0.12(m)(m)
1 Jan 202131 Dec 2021(m)0.70(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 43.76M ■ Earnings -96.27M — Profit margin -220.01%

-134.89M-221.0%-1.85M-140.6%131.19M-60.1%264.23M20.4%30 Sept 2025: revenue 150.86M; earnings 21.57M; profit margin 14.30%30 Sept 202531 Dec 2025: revenue 225.61M*; earnings 43.67M*; profit margin 19.36%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 37.23M; earnings -53.16M; profit margin -142.79%31 Mar 202630 Jun 2026: revenue 43.76M; earnings -96.27M; profit margin -220.01%30 Jun 2026

31 Dec 2025 ■ Revenue 564.17M ■ Earnings 37.00M — Profit margin 6.56%

-67.70M-0.8%165.49M2.0%398.68M4.8%631.87M7.6%31 Dec 2022: revenue 450.89M; earnings 15.50M; profit margin 3.44%31 Dec 202231 Dec 2023: revenue 433.14M; earnings 4.90M; profit margin 1.13%31 Dec 202331 Dec 2024: revenue 482.04M; earnings 0.90M; profit margin 0.19%31 Dec 202431 Dec 2025: revenue 564.17M; earnings 37.00M; profit margin 6.56%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$1.39(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$1.39High(m)Average(m)Low(m)2025-09-292026-09-29

Recent news

View more →

(m)

YouTube videos mentioning ORGO

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-12; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$-84.19M
Profit margin
-18.40%
Return on assets · 12 month
-19.41%
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
854.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
662.93K
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-6.42%*
Total return · month
-20.40%*
Total return · quarter
-42.77%*
Total return · half year
-39.52%*
Total return · year to date
-73.26%*
Total return · 1 year
-67.49%*
Total return · 3 years
-56.45%*
Total return · 5 years
-90.60%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$457.45M
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

ORGANOGENESIS HOLDINGS INC. Overview

View more →

(m)

(m)

SEC CIK
1661181
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
85 DAN ROAD, CANTON, Massachusetts, 02021, United States
Fiscal year end
1231
Phone
781-575-0775

Similar stocks

Stock NameCountryMarket CapPE Ratio
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
PepGen Inc. (PEPG)United States$0.186B-1.73
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91
Zentalis Pharmaceuticals, Inc. (ZNTL)United States$0.196B-2.48
Tonix Pharmaceuticals Holding Corp. (TNXP)United States$0.166B-1.34
Minerva Neurosciences, Inc. (NERV)United States$0.165B-0.66
ORAMED PHARMACEUTICALS INC. (ORMP)$0.199B1.13
ADC Therapeutics SA (ADCT)$0.163B-1.39
LIFECORE BIOMEDICAL, INC. DE (LFCR)United States$0.163B-8.50